These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 19004846

  • 1. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
    Krishna R, Bergman AJ, Jin B, Garg A, Roadcap B, Chiou R, Dru J, Cote J, Laethem T, Wang RW, Didolkar V, Vets E, Gottesdiener K, Wagner JA.
    J Clin Pharmacol; 2009 Jan; 49(1):80-7. PubMed ID: 19004846
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel LM, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA.
    Clin Pharmacol Ther; 2008 Dec; 84(6):679-83. PubMed ID: 18580870
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

  • 5. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D.
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [Abstract] [Full Text] [Related]

  • 6. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP, Dansky HM, Davidson M, Gotto AM, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P, DEFINE investigators.
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [Abstract] [Full Text] [Related]

  • 7. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
    Krishna R, Stypinski D, Ali M, Garg A, Gendrano IN, Maes A, DeGroot B, Liu Y, Li S, Connolly SM, Wagner JA, Stoch SA.
    Biopharm Drug Dispos; 2011 Dec; 32(9):525-9. PubMed ID: 22031172
    [Abstract] [Full Text] [Related]

  • 8. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA.
    Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
    [Abstract] [Full Text] [Related]

  • 9. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.
    Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J, Wagner JA.
    J Clin Pharmacol; 2009 Apr; 49(4):398-406. PubMed ID: 19246722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ, Burnett JR.
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
    Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF.
    Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
    Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL.
    Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.